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SCIENTIFIC ARTICLE
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Abstract
Objective To determine and compare the value of 18F–fluoro-
2-deoxy-D-glucose positron emission tomography/computed
tomography (FDG-PET/CT) to blind bone marrow biopsy
(BMB) of the posterior iliac crest in detecting metastatic bone
marrow involvement in newly diagnosed Ewing sarcoma.
Materials and methods This retrospective study included 20
patients with newly diagnosed Ewing sarcoma who
underwent pretreatment FDG-PET/CT and a total of 38 blind
BMBs (two unilateral and 18 bilateral) of the posterior iliac
crest. FDG-PET/CT scans were evaluated for bone marrow
involvement, both in the posterior iliac crest and other sites,
and compared to blind BMB results.
Results FDG-PET/CTwas positive for bone marrow involve-
ment in 7/38 posterior iliac crests, whereas BMB was positive
in 5/38 posterior iliac crests. FDG-PET/CT and BMB results
in the posterior iliac crest agreed in 36/38 cases (94.7%, 95%
confidence interval [CI]: 82.7–98.5%). On a patient level,
FDG-PET/CT was positive for bone marrow involvement in
4/20 patients, whereas BMB of the posterior iliac crest was
positive in 3/20 patients. On a patient level, FDG-PET/CTand
BMB results agreed in 19/20 patients (95.0%, 95% CI: 76.4–
99.1%). The only discrepancies between FDG-PET/CT and
BMB were observed in two BMBs of one patient. Both
BMBs in this patient were negative, whereas FDG-PET/CT
indicated bilateral posterior iliac crest involvement and also
extensive bone marrow involvement elsewhere.
Conclusions FDG-PET/CT appears to be a valuable method
for metastatic bone marrow assessment in newly diagnosed
Ewing sarcoma. The routine use of blind BMBof the posterior
iliac crest should be reconsidered when FDG-PET/CT is
available.
Keywords Biopsy . Bone . Ewing sarcoma . Pet-Ct . Tumor
staging
Introduction
Ewing sarcoma is an aggressive primary tumor of bone and
soft tissue occurring at any age with a peak incidence in ado-
lescents and young adults [1], and an overall incidence of
approximately 2.93 cases/1,000,000 [2]. Approximately 26–
28% of newly diagnosed Ewing sarcoma patients have been
reported to present with distant metastases, with lung and
bone marrow being the most frequent sites of metastatic dis-
ease [2]. Metastatic status at diagnosis is the strongest prog-
nostic factor across different treatment strategies [1]. Five-
year overall survival is approximately 30% for patients with
initially metastatic disease [1]. Furthermore, metastatic status
is the most important factor in the risk-adapted treatment strat-
egy that is currently employed in both North America and
Europe [1]. Accurate staging is thus crucial because of its
prognostic and therapeutic implications.
Patients with newly diagnosed Ewing sarcoma usually un-
dergo conventional radiographic and magnetic resonance im-
aging (MRI) examinations of the primary tumor site, chest
computed tomography (CT), whole-body bone scintigraphy,
and blind bone marrow biopsy (BMB) of the posterior iliac
crest (usually bilateral). BMB, however, is an invasive
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procedure that carries a small but nonnegligible risk of
(hemorrhagic) complications [3], and is often performed un-
der general anesthesia in this mainly pediatric population.
Meanwhile, 18F–fluoro-2-deoxy-D-glucose (FDG) positron
emission tomography (PET)/CT is increasingly used as a
new staging method in Ewing sarcoma [4]. The exact role of
FDG-PET/CT and its value compared to the traditionally used
staging procedures is still unclear. However, one of the advan-
tages of FDG-PET/CT is that it can visualize the entire body,
including the bone marrow. It can be hypothesized that FDG-
PET/CT may replace blind BMB of the posterior iliac crest if
it is sufficiently accurate to detect bone marrow involvement.
The purpose of this study was therefore to determine and
compare the diagnostic value of FDG-PET/CT to blind BMB
of the posterior iliac crest in detecting metastatic bone marrow
involvement in newly diagnosed Ewing sarcoma.
Materials and methods
Study design and patients
The local institutional review board approved this retrospec-
tive study and waived the requirement for informed consent.
The database of our tertiary university hospital, which is also a
referral center for sarcoma patients, was searched for all pa-
tients who were newly diagnosed with Ewing sarcoma and
who underwent pretreatment FDG-PET/CT and BMB be-
tween August 2009 and August 2017. Inclusion criteria for
this study were: newly diagnosed and histologically proven
Ewing sarcoma, and availability of pretreatment FDG-PET/
CT and blind BMB (either bilateral or unilateral) of the pos-
terior iliac crest. Exclusion criteria for this study were: previ-
ously treated Ewing sarcoma and time interval of more than
30 days between FDG-PET/CT and BMB.
FDG-PET/CT acquisition and evaluation
FDG-PET/CT was performed using an integrated PET/CT sys-
tem (Biograph mCT PET/CT, Siemens, Knoxville, TN, USA)
that was EANM/EARL (European Association of Nuclear
Medicine/ResEARch 4 Life) accredited [5]. All patients fasted
for at least 6 h before 3 MBq FDG/kg body weight was injected
intravenously. Blood glucose levels were checked to be less than
11 mmol/l before FDG injection. PET/CT scanning was per-
formed from cranial vertex to midthighs approximately 60 min
after FDG administration, with 3min per bed position. In patients
with primary tumors in the lower extremities, a true whole-body
FDG-PET/CT (from cranial vertex to toes) was performed. Low-
dose CTwith 100 kVp and 30 mAs was performed for attenua-
tion correction and anatomical correlation. Data reconstruction
was performed according to EANM guidelines [5]. FDG-PET/
CT scans were evaluated by a board-certified nuclear medicine
physician (A.W.J.M.G.) who knew the diagnosis and primary
location of Ewing sarcoma in each patient, but was blinded to
BMB results and other imaging findings. Both posterior iliac
crests were assessed for bone marrow involvement, which was
defined as focal FDG uptake exceeding background bone mar-
row FDG uptake (with or without lytic or sclerotic changes on
corresponding low-dose CT) or non-FDG-avid lytic or sclerotic
bone changes on low-dose CT. Other parts of the skeleton (out-
side of the primary tumor location) and extraskeletal sites were
also assessed for metastatic disease.
BMB acquisition and interpretation
Unilateral or bilateral blind BMBs of the posterior iliac crest
were performed by (pediatric) oncologists. Younger patients
underwent general anesthesia, conscious sedation was applied
in older children, and adults only underwent local anesthesia.
BMB samples were interpreted for bone marrow involvement
by one of the attending expert bone pathologists who was
blinded to FDG-PET/CT results.
Data analysis
Percentage of agreement between FDG-PET/CT and BMB in
detecting bone marrow involvement in the posterior iliac crest
was calculated, along with 95% confidence intervals (CIs).
Percentage of agreement between FDG-PET/CT and BMB
on a patient level with regard to the detection of bone marrow
involvement anywhere in the body (i.e., also considering bone
marrow lesions outside of the posterior iliac crest detected at
FDG-PET/CT) was also calculated, along with 95% CIs.
Results
Patients
A total of 22 patients were potentially eligible for inclusion. One
of these patients was excluded because BMBwas not performed,
and one patient was excluded because the time interval between
FDG-PET/CT and BMB was 115 days. Thus, 20 patients (12
males and eight females, with mean age of 15.9 ± 13.1 years
[range, 5–57 years]) were finally included. Seventeen patients
had primary bone Ewing sarcoma (pelvis [n = 5], femur
[n = 2], humerus [n = 2], rib/chest wall [n = 2], sacrum [n = 2],
clavicle [n = 1], lumbar vertebra [n = 1], temporal bone [n = 1],
and tibia [n = 1]), whereas three patients had primary
extraosseous Ewing sarcoma (soft tissues around the knee
[n = 1], femur [n = 1], and intradural cervical spine [n = 1]).
Eighteen patients underwent bilateral blind BMB and two pa-
tients underwent unilateral blind BMB of the posterior iliac crest,
yielding a total of 38 BMBs. In 14 patients, FDG-PET/CT was
performed before BMB, and in six patients FDG-PET/CT was
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performed after BMB. Mean time interval between FDG-PET
and BMBwas 6.0 ± 6.3 days (range, 0–22 days). Fifteen patients
had localized disease, whereas five patients had metastatic dis-
ease according to FDG-PET/CT (lymph nodemetastases [n = 1],
lymph node and lung metastases [n = 1]), lymph node and bone
marrow metastases [n = 1], lymph node, lung and bone marrow
metastases [n = 1], and lymph node, lung, liver, pancreatic and
bone marrow metastases [n = 1]).
FDG-PET/CT vs. BMB
FDG-PET/CT was positive for bone marrow involvement in
seven posterior iliac crests and negative for bone marrow in-
volvement in 31 posterior iliac crests, whereas BMB was pos-
itive in five and negative in 33 posterior iliac crests (Table 1).
FDG-PET/CT and BMB results in the posterior iliac crest were
in agreement in 36/38 cases (94.7%, 95% CI: 82.7–98.5%).
On a patient level, FDG-PET/CT was positive for metastatic
bone marrow involvement in four patients (in three of these
patients FDG-PET/CTalso showed bonemarrow lesions outside
the posterior iliac crests) and negative for metastatic bone mar-
row involvement in 16 patients, whereas BMB of the posterior
iliac crest was positive in three and negative in 20 patients
(Table 2). On a patient level, FDG-PET/CT and BMB results
were in agreement in 19/20 patients (95.0%, 95% CI: 76.4–
99.1%).
The only discrepancies between FDG-PET/CT and BMB
were observed in two BMBs of one patient. Both BMBs in
this patient were negative, whereas FDG-PET/CT suggested
bilateral posterior iliac crest bone marrow involvement and
also extensive bone marrow involvement elsewhere in the
axial skeleton, and both humeri and femora (Fig. 1).
Six FDG-PET/CT-positive posterior iliac crests exhibited
focally increased FDG uptake without visible CT changes,
whereas one FDG-PET/CT positive posterior iliac crest was
non-FDG-avid with sclerotic changes on CT (Fig. 2).
Discussion
The results of this study show that FDG-PET/CTand blindBMB
of the posterior iliac crest are in agreement in almost all cases.
The only disagreement between the two procedures in this series
was observed in one patient in whom bilateral blind BMBs of the
posterior iliac crest were negative, whereas FDG-PET/CT was
positive at both posterior iliac crests. Although repeated CT-
guided bone biopsies of FDG-avid bone foci were not performed
in this patient, the fact that FDG-PET/CT showed multiple other
bone lesions is highly suggestive that blind BMB was false neg-
ative in this patient due to sampling errors. Furthermore, in three
other patients in whom FDG-PET/CTand blind BMBwere con-
cordantly positive at the posterior iliac crest, FDG-PET/CT de-
tected additional bone marrow metastases outside the posterior
iliac crests. Such information is important, because the number of
bone lesions has been shown to correlate with a worse prognosis
[1, 6]. The findings of this study thus support the hypothesis that
FDG-PET/CTmay replace blind BMB of the posterior iliac crest
in Ewing sarcoma. On another note, FDG-PET/CT may also be
used to screen for bone marrow metastases, and, if positive,
subsequent CT-guided bone biopsy may be performed for histo-
logical confirmation. Given the fact that around 10% of patients
have been reported to have bone marrow metastasis [7], approx-
imately 90% of patients can be spared invasive bone biopsy with
such an approach. However, this latter hypothesis was not tested
in the present study.
The recently published National Comprehensive Cancer
Network (NCCN) guidelines state that BMB should be consid-
ered in the workup of Ewing sarcoma, and that screeningMRI of
the spine/pelvis is also recommended in lieu of, or in addition to,
BMB [7]. The current guidelines of the European Society for
Medical Oncology (ESMO) mention that BMBs from sites dis-
tant to the primary or known metastatic lesions may be consid-
ered, in the face of a very low incidence of bone marrow metas-
tases in localized disease, especially if PET scan was carried out
[8]. Although these guidelines recognize the drawbacks of blind
BMB and the potential value of imaging in this setting, ongoing
studies such as the Euro Ewing 2012 trial still perform standard
BMB in each patient [9]. Furthermore, the NCCN and ESMO
guidelines are mostly based on expert opinions [7, 8], and actual
scientific data on the value of FDG-PET/CT compared to BMB
are still very scarce. One previous study by Newman et al. [10]
included 69 patients with newly diagnosed Ewing sarcoma who
underwent both (stand-alone) FDG-PET and (either unilateral or
bilateral) BMB of the iliac crest. On a patient level, FDG-PET
and BMB were positive for bone marrow metastasis in 9/69 and
6/69 patients, respectively [10]. FDG-PET suggested bone mar-
row metastasis in three patients who had negative BMB results,
while none of the six patients with a positive BMB result were
negative for bone marrow metastasis on FDG-PET [10]. These
findings are completely in line with the results of the present
Table 1 Cross-tabulation of FDG-PET vs. BMB results for bone
marrow involvement in the posterior iliac crest for a total of 38 BMBs
BMB positive BMB negative
FDG-PET/CT positive 5 2
FDG-PET/CT negative 0 31
Table 2 Cross-tabulation of FDG-PET vs. BMB results for bone
marrow involvement on a patient level for a total of 20 patients
BMB positive BMB negative
FDG-PET/CT positive 3 1
FDG-PET/CT negative 0 16
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study. To the best of our knowledge, there are no other studies
that have explicitly compared FDG-PET(/CT) to BMB in Ewing
sarcoma. Therefore, further research is needed to definitely es-
tablish FDG-PET/CT as a (partial) alternative to BMB.
This study had several limitations. First, the sample size was
relatively small and the retrospective study design may have
introduced selection bias. Future larger prospective studies are
thus necessary. On another note, the results of this studymay also
be used by a future meta-analysis on this topic. Second, FDG-
PET/CT was performed from cranial vertex to midthighs in pa-
tients with non-lower extremity primary tumors, and the region
caudal to the midthighs was thus not assessed in these patients.
a b
c
Fig. 1 Disagreement between FDG-PET/CT and blind BMB of the
posterior iliac crest in a 15-year-old boy with Ewing sarcoma. Coronal
maximum intensity projection FDG-PET (a) shows the primary tumor in
the left chest wall (continuous arrow), adjacent mediastinal lymph node
metastases (dashed arrow), and extensive bone marrow metastases in
both humeri, multiple ribs, vertebrae, sacrum, pelvic bone, and both
proximal femora (arrowheads). Axial FDG-PET/CT images (b, c) show
increased FDG uptake in both posterior iliac crests (continuous arrows)
and several FDG-avid foci in the sacrum (arrowheads), in keeping with
bone marrow metastases. Note that both posterior iliac crests are not
entirely involved according to FDG-PET/CT (no increased FDG uptake
is seen in the left posterior iliac crest in b, and no increased FDG uptake is
seen in the right posterior iliac crest in c. Blind BMB of both posterior
iliac crests showed normal maturing trilineage hematopoiesis without any
malignant cells. This patient was not re-biopsied to histologically confirm




Fig. 2 Non-FDG-avid sclerotic bone marrow involvement of the right
posterior iliac crest in a 10-year-old boy with Ewing sarcoma. Coronal
maximum intensity projection FDG-PET (a), axial FDG-PET/CT (b),
and low-dose CT with soft tissue window settings (c) show the slightly
FDG-avid primary tumor in the right gluteal muscles (continuous arrow).
Although no increased FDG uptake is seen in the right posterior iliac crest
(b), low-dose CTwith bone window settings shows extensive sclerosis in
the right posterior iliac crest (dashed arrow). Blind BMB of the right
posterior iliac crest showed involvement with Ewing sarcoma. Of interest,
bone scintigraphy (e) that was performed before FDG-PET/CT also
showed pathological activity in the right posterior iliac crest (arrowheads)
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Furthermore, although low-dose CTwas performed in this study
with (mainly) pediatric patients, a full-dose CT may be consid-
ered instead, since the CT component is a stand alone for the
definition of a positive FDG-PET/CT. Third, FDG PET/CT
should preferably be done prior to BMB, but this was not the
case in six of 20 patients. However, previous work has shown
that performing BMB before FDG-PET/CT does not result in
any visually increased FDG uptake that is regarded as patholog-
ical [11]. Furthermore, BMB-induced anatomical CT changes at
the posterior iliac crest are very uncommon in patients who un-
dergo BMB before FDG-PET/CT, and, if present, have a char-
acteristic millimetric cylindrical shape that is not to be confused
with pathology [11]. Thus, it is unlikely that BMB has affected
FDG-PET/CT interpretation in these six patients. Fourth, FDG-
avid bone lesions outside of the posterior iliac crest were not
biopsied, as mentioned previously. Fifth, FDG-PET/CT was
not compared to bone scintigraphy or MRI. One previous study
by Ulaner et al. [12] compared FDG-PET/CT to bone scintigra-
phy in 60 newly diagnosed Ewing sarcoma patients, however
without reporting their diagnostic values compared to BMB. In
their study, 40 primary malignancies had a lytic CT appearance,
three were sclerotic, and 13 involved only soft tissue [12]. In 11
of 12 patients with bone marrow metastases, these were detected
on FDG-PET/CT, with the one false-negative occurring in a
sclerotic primary tumor [12]. In nine of 12 patients with bone
marrow metastases, these were detected on bone scintigraphy,
with the three false-negatives occurring in patients with lytic
primary tumors [12]. Ulaner et al. [12] concluded that when
Ewing sarcoma is lytic, bone scintigraphy does not add to staging
performed by FDG PET/CT, and may be omitted. However, in
the uncommon situation of primary sclerotic Ewing sarcoma of
bone, Ulaner et al. [12] stated that bone scintigraphy may detect
osseous metastases not detected by FDG-PET/CT. The addition-
al value of bone scintigraphy to FDG-PET/CT in primary
extraosseous Ewing sarcoma is still unclear [12]. In the present
study, one patient had non-FDG-avid BMB-proven bone in-
volvement of the right posterior iliac crest that appeared sclerotic
on corresponding low-dose CT (Fig. 2). This example demon-
strates that both the PET and CT portion of the examination
should always be reviewed to detect bone marrow metastases
in Ewing sarcoma. Unlike bone scintigraphy that only demon-
strates osteoblastic activity, both FDG-PET and MRI are also
able to assess the bone marrow, similar to BMB. There are no
studies that have directly compared FDG-PET/CT to (whole-
body) MRI and BMB in newly diagnosed Ewing sarcoma.
However, it should be noted that whole-body MRI is still time-
consuming, and MRI is less sensitive than CT for detecting lung
metastasis. Therefore, at present, FDG-PET/CT seems to be the
primary whole-body staging method of choice in Ewing
sarcoma.
In conclusion, FDG-PET/CTappears to be a valuable method
for metastatic bone marrow assessment in newly diagnosed
Ewing sarcoma. The routine use of blind BMB of the posterior
iliac crest should be reconsidered when FDG-PET/CT is
available.
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